Since neural progenitor cells can engraft stably into brain tumors and differentiate along the neuronal and glial line, we tested the hypothesis that transplanted cytosine deaminase (CD)-expressing ST14A cells (an immortalized neural progenitor cell line) can convert locally 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU) and produce a regression of glioma tumors. ST14A, retrovirally transduced with the E. coli CD gene, showed a strong bystander effect on glioma cells as assessed by in vitro assay. Intracerebral injection of C6 glioma cells generated a rapidly growing tumoral mass. DiI prelabeled ST14A, coinjected into the rat brain with C6 glioma cells, survived in the tumoral mass up to 10 days and their number was not affected by in vivo 5-FC treatment. In contrast, a significant decrease of the glioma tumoral mass (À50%) was observed in 5-FC-treated rats. 5-FC had no effect on the tumor in the absence of CD-expressing ST14A cells. Our results support the feasibility of systems based on intratumoral transplantation of prodrug-converting cells for brain tumor therapy.
A n approach for cancer gene therapy is based on the delivery of a gene encoding an enzyme that transforms an inert prodrug into a toxic product. 1 Thus, cells expressing the so-called 'suicide gene' are killed following prodrug administration. The cytosine deaminase (CD) gene is an example of such a gene: 1, 2 this fungal and bacterial enzyme catalyzes the deamination of nontoxic 5-fluorocytosine (5-FC) in the highly toxic drug 5-fluorouracil (5-FU). 3 Since mammalian cells do not express significant amounts of CD, 5-FC is nontoxic to them at concentrations that result in strong antimicrobial activity. The direct transfer of the E. coli CD gene to the tumoral cells makes these cells selectively sensitive to the toxic effects of 5-FC. 3, 4 An interesting property of the enzyme/prodrug systems is the 'bystander effect', 5 the death of unmodified tumoral cells adjacent to genetically modified cells. Since only a minor fraction of the tumoral cell population can be genetically modified, by the available gene-transfer systems, the therapeutic efficacy relies on the bystander effect. 6 In the case of the CD/5-FC system, 5-FU released by CD-expressing cells is able to diffuse and kill adjacent unmodified cancer cells. However, the rapid death of the prodrug-converting cells represents a major limitation of this form of gene therapy. A resistance of prodrugconverting cells to the toxic effects of the drug should enhance and prolong the bystander effect.
In the case of malignant gliomas, the most common incurable brain tumors, a novel strategy that can overcome this limitation is based on the intratumoral implantation of neural stem/progenitor cells. 7 These cells can be engineered in vitro to produce therapeutic molecules and, after in vivo intratumoral transplantation, they could differentiate along the glial and neuronal lineage. It is reasonable to hypothesize that the in vivo arrest of proliferation, because of neural differentiation, can decrease the sensitivity of these cells to the cytotoxic effects of 5-FU and, therefore, prolong the diffusion of 5-FU and its metabolites into surrounding tumor cells. Our aim was to test the feasibility of an experimental therapy combining the use of embryonic striatal conditionally immortalized ST14A cells 8 with the 5-FC/ CD system.
Materials and methods
Cell lines: ST14A cells and C6 glioma ST14A, an immortalized neural progenitor cell line, 8 was grown in Dulbecco's modified Eagle medium (DMEM, Life Technologies, Paisley, Scotland), 4.5 g/l d-glucose, supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum, 2 mM l-alanyl-l-glutamine, penicillinstreptomycin (50 U-50 mg/ml). C6 rat glioma cell lines were maintained in DMEM, 1 g/l d-glucose, supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum, 2 mM l-alanyl-l-glutamine, penicillin-streptomycin (50 U-50 mg/ml) and incubated at 371C in a humidified atmosphere of 5% CO 2 , 95% air. The culture medium was changed twice a week.
CD recombinant plasmids
The plasmid pCD2, containing the entire coding sequence of E. coli CD gene, was kindly provided by Michael Blaese. 4 For this study, the CD gene was subcloned in the retroviral vector pLXSP (pLXSP-CD). PLXSP has been obtained from PLXSN (Clontech, Palo Alto, CA) by replacing the neomycin resistance gene with puromycin resistance gene.
ST14A cells infection with pLXSP-CD
Transfection of packaging cell lines (Retropack PT67, Clontech, CA, USA) was performed using the 'Lipofectamine 2000 Reagent' (Gibco BRL, Gaithersburg, MD) and viral supernatants were used for infection of ST14A. Clonal selection was performed by puromycin treatment.
RNA extraction and RT-PCR
Total RNA was extracted from selected cell clones using the 'TRIzol reagent' (GIBCO-BRL, Life Technologies, Gaithersburg, MD). Reverse transcription was performed using total RNA, RNase H À reverse transcriptase (Superscript II, Gibco BRL, Life Technologies, Gaithersburg, MD) and random primer hexamers. The cDNA was amplified with DyNAzyme TM II DNA polymerase (Finnzymes, Espoo, Finland).
A CD fragment (1302 bp) was amplified with the following primers: forward 5 0 -GGAGGCTAACAATGTCGAAT-3 0 , reverse 5 0 -CCAGTCGTTCAACGTTTGTA-3 0 . The amplification program was as follows: a denaturation step of 3 minutes, followed by 35 cycles at 951C for 1 minute, 541C for 2 minutes and 721C for 3 minutes. Amplification products were examined by electrophoresis in 1.8% agarose 1 Â TAE gels and ethidium bromide staining. ) were plated in 96-well plates 'Nunclon TM Microwell TM ' (Nalge Nunc International, Naperville, IL, USA) and incubated at 331C. After 24 hours, cells were treated with 5-FU (Acros Organics, Fisher Scientific, UK) or 5-FC (Sigma-Aldrich, St Louis, MO) (0.001-10 mM). Untreated cells were used as controls. Microplates were incubated at 331C in a humidified atmosphere of 5% CO 2 , 95% air for 5-7 days and then cytotoxicity was measured with a colorimetric assay based on the use of the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide). 9 The results were read on a multiwell scanning spectrophotometer, using a wavelength of 570 nm. Some microplates were shifted at the nonpermissive temperature (391C) 24 hours after initial cell plating, and after 2 days, cells were treated with 5-FU or 5-FC (0.001-10 mM).
Microplates were incubated at 391C in a humidified atmosphere of 5% CO 2 , 95% air for 5-7 days before measuring cytotoxicity as described.
In vitro 'bystander effect' experiments
The 'bystander effect' was analyzed by coculture experiments. CD-negative (CDÀ) and CD-positive (CD+) ST14A cells were plated (0.9 Â 10 5 cells) on micro square cover glasses (20 Â 20 mm 2 ) in DMEM plus 10% FCS, incubated at 331C for 1-2 days, and then shifted at 391C for 2 days. Each square cover glass was then transferred in a 60 mm dish (Falcon) and 5-FC was added to the medium (0.05-1 mM).
C6 glioma cells were chosen as target cells. They were plated on a 100 mm dish (2 Â 10 5 cells/dish) containing microround cover glasses (11 mm diameter) and maintained in DMEM plus 10% FCS for 24 hours at 391C. Three round cover glasses, with attached C6 cells, were transferred in the 60 mm dish containing a single square cover glass with adherent ST14A cells pretreated for 24 hours with 5-FC. Incubation in the presence of 5-FC was continued at 391C in a humidified atmosphere of 5% CO 2 , 95% air for 3 days before transferring the round cover glasses in 24-well plates to evaluate the cytotoxicity by the MTT colorimetric assay.
'In vivo' intracerebral implantation of ST14A and C6 cells
The experiments were carried out in accordance with the National Institute of Health Guide of Care and Use of Laboratory Animals. Adult Sprague-Dawley (250 g) rats were used as host animals and intracerebral transplantations were made under anesthesia with ether, using a David Kopf stereotaxic apparatus. The injection was made unilaterally at striatal level using the following parameters in relation to bregma:
10 The cells were injected in phosphate buffer saline (PBS, pH 7.4, 1.5 ml) using a 10 ml Hamilton syringe fitted with a 30-gauge needle. Preliminary experiments were performed to establish the optimal number of C6 cells and ST14A cells to be injected. Two groups of animals (10 rats per group) were operated: (1) rats injected with a mixture of CD+ ST14A cells/C6 glioma cells (8 Â 10 4 /2 Â 10 4 ) and (2) rats injected with a mixture of CDÀ ST14A cells/C6 glioma cells (8 Â 10 4 /2 Â 10 4 ). After 3 days, five rats per group received intraperitoneal injections of 5-FC solution (50 mg/3.2 ml PBS) twice a day for 7 days. Control animals were similarly injected with vehicle only. At 10 days after transplantation (7-day treatment), the animals were killed by decapitation in deep ether anesthesia. Brains were frozen using isopentane, cooled in liquid nitrogen, and were serially sectioned at 14 mm throughout the striatum Prodrug-converting neural progenitor cells V Barresi et al using a cryostat. Subsequently, the sections were dried at room temperature, fixed in 4% paraformaldehyde for 15 min, washed in PBS 1 Â and stained by cresyl violet. The entire tumor mass was sectioned and the area of each section was measured using the NIH Image software (rsbweb.nih.gov); the total area obtained summing up the single cross-sectional areas was used as an index of the tumor mass.
In vivo transplantation of in vitro prelabeled CD+ cells
Labeling of CD+ ST14A cell monolayers was performed by adding 9 mM 1,1 ) and killed at 1, 3, 10 days after implantation. Three animals bearing a mixture of prelabeled CD+ ST14A cells/C6 cells were treated with 5-FC for 1 week starting 3 days after implantation. Control animals were similarly injected with vehicle only.
Results
Effects of the 5-fluoropyrimidines (5-FU and 5-FC) on CDÀ and CD+ ST14A cells at permissive temperature (331C) and nonpermissive temperature (391C)
To evaluate the effects of the 5-fluoropyrimidines, 5-FU and 5-FC, on ST14A cells, a cytotoxic assay was performed at 33 and 391C. ST14A is an immortalized neural progenitor cell line derived from embryonic rat striatum primordia (E14) by retroviral transduction of the temperature-sensitive mutant of the SV40 large Tantigen. 8 At 331C, ST14A cells proliferate and express Nestin, a marker for neural stem cells, whereas at the nonpermissive temperature (391C) cell growth becomes restricted in coincidence with the reduced expression of the T-antigen. As shown in Figure 1 , at the permissive temperature (331C), ST14A cells were sensitive to 5-FU treatment with an ED 50 value equal to 0.01 mM; in contrast, at the nonpermissive temperature (391C), the sensitivity of ST14A to 5-FU cytotoxicity was strongly attenuated. Both at 33 and 391C 5-FC did not affect cell growth up to 1 mM.
CD+ ST14A cells were obtained by retroviral transduction of the E. coli gene and different clones were selected by puromycin treatment. The expression of CD transcripts was evaluated by RT-PCR and clones 2 and 10 were chosen for further experiments because of their relatively high expression (Fig 2) . As shown in Figure 3 , CD+ cells acquired a clear sensitivity to the cytotoxic action of 5-FC, thus confirming the enzymatic conversion to the toxic 5-FU. At 331C, the treatment with increasing concentrations of the prodrug 5-FC (0.001-10 mM) had no effect on CDÀ ST14A, but arrested the growth of CD+ clones 2 and 10 (ED 50 0.1 mM).
CD+ ST14A cells generated a strong 'bystander effect' in vitro
To assess the ability of the CD+ clones to kill neighboring cancer cells, we used a coculture system of ST14A cells and rat C6 glioma cells. C6 cells alone were highly sensitive to 5-FU (ED 50 0.01 mM), but insensitive to 5-FC up to 10 mM (Fig 4) . C6 cells grown with CD-ST14A cells remained insensitive to 5-FC. On the contrary, the presence of CD+ ST14A cells made C6 cells highly sensitive to the dose-dependent cytotoxic effect of 5-FC (Fig 5) . 
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Phase-contrast microphotographies in Figure 6 show the morphological appearance of C6 cell monolayers cocultured with CD+ ST14A cells and treated with different concentrations of 5-FC (0.5-1 mM). The decreased growth of treated cells (Fig 6, panels 2 and 3 ) in comparison to untreated controls (panel 1) is clear. As expected, 1 mM 5-FC failed to affect the growth and viability of C6 cells cocultured with CD-ST14A cells (Fig  6, panel 4) .
In vivo intracerebral transplantation of CD+ ST14A cells reduced the glioma mass following 5-FC treatment
In order to assess the survival and migratory pattern of transplanted ST14A cells, they were prelabeled in vitro with DiI and coinjected with C6 cells in the adult rat striatum. ST14A cells, 1 day after transplantation, were uniformly labeled and remained localized to the area of injection (Fig 7, 1d) . At 3 days postgrafting, a moderate migration through tumoral tissue was observed (Fig 7, 3d ) and such migration, far from the injection site, continued in the following week. Transplanted ST14A cells, widely scattered in the tumoral mass, survived up to 10 days (the longest time examined) both in the presence and absence of in vivo 5-FC treatment (Fig 7, 10d and 10d/5-FC) .
The ability to decrease the proliferation of cancer cells was investigated by intracerebral transplantation of CD+ ST14A cells. As shown in Figure 8 , an intracerebral injection of C6 cells generated a rapidly growing tumor mass. The brain tumors were generally well-circumscribed and caused compression of adjacent tissues. However, focal perivascular glioma infiltration into adjacent brain tissue occurred. A significant decrease of the tumoral mass was observed in 5-FC-treated rats (À50% in comparison to control) (Fig 8b, c) , when CD+ cells were coinjected with the glioma cells. 5-FC had no oncolytic effect in the presence of CD-ST14A cells (Fig 8c) .
Discussion
Gliomas are among the most aggressive and common primary tumors in the brain and to date the prognosis is poor. The enzyme/prodrug gene therapy is an additional therapeutic option to the surgery, chemotherapy and radiotherapy for the treatment of the tumors. 
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Essentially, two prodrug-activation systems, out of 13 developed over the last 15 years, are the most known: activation of gancyclovir by viral thymidine kinase and activation of 5-FC to 5-FU 1 by CD. Both systems rely on the 'bystander effect' that requires cell-to-cell contact in the gancyclovir/thymidine kinase system or is mediated by facilitated diffusion in the CD/5-FC. 11 5-FC and 5-FU are small and highly water-soluble molecules; they penetrate well into most body sites including cerebrospinal, vitreous and peritoneal fluids and do not require cell-to-cell contact for intercellular transfer: 12, 13 this trait was decisive in our choice of this system because it is known that malignant glioma cells can be deficient in connexin expression and gap junctional communication. [14] [15] [16] [17] [18] Results reported in this paper suggest that intratumoral transplantation of neural progenitor cells, engineered to produce locally 5-FU, may represent a useful strategy for the induction of tumor regression. Indeed, the direct intratumoral production of 5-FU might minimize its systemic toxicity.
In our model we have chosen ST14A cells, 8 neural progenitor cells that can engraft stably into host adult brain and survive very well for 2-6 weeks without tumor formation. 19 These immortalized cells behave as multipotent neural progenitors and, after brain transplantation, differentiate to some extent to give rise to glia and neuronal-like cells. 8, 19 As shown in the present work, by in vitro and in vivo experiments, change in the differentiation state of ST14A cells, from immature to postmitotic conditions, is accompanied by an increased resistance to 5-FU toxic effects.
Indeed, intracerebrally transplanted CD-expressing ST14A cells survived following 1-week treatment with 5-FC and decreased the tumor growth, thus suggesting that they could provide a continuous source of 5-FU to the surrounding tumor cells. While this work was in progress, Aboody et al 20 Prodrug-converting neural progenitor cells V Barresi et al cell line (murine C17.2), 21 engineered to express CD, as a potential approach to the treatment of brain tumors. This cell line showed a remarkable ability to migrate throughout the CNS and a tropism towards tumor tissues, even when injected at distant sites. 20 Aboody et al 20 showed the utility of this type of cell transplantation as a continuous local source of an antitumoral agent. Although the extensive migratory capacity of neural stem cells, such as murine C17.2, 20 can represent an advantage for clinical use, it also implicates a higher risk of uncontrolled dissemination of the cells in the brain parenchyma that could contribute to toxic effects on normal cells. The present results show that engineered progenitor cells, such as ST14A, with moderate migratory properties, can exert a useful antitumoral action. The choice of the two different systems may depend on the specific clinical conditions. Implantation of engineered neural progenitor cells might be performed after surgical resection of the glioma tissue, in order to decrease the probability of tumor recurrence. A local antimitotic activity could also play an antiangiogenic role that could contribute to the therapeutic action. More studies are necessary to establish the proper cell lines and protocols for the treatment of human patients. 
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